

# The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

NCT06599697

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Alabama at Birmingham
Enrollment	12 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Age  $\geq$  16 years
- Anti-HMGCR antibody positive
- MMT-8 score  $\leq$  142 (range 0-160)
- Serum CK  $\geq$  5x upper limit of normal
- Anti-HMGCR IMNM disease duration  $\leq$  36 months at screening

... and 3 more (see full listing online)

### Exclusion (20)

- Oral glucocorticoid (GC) daily dose  $\geq$  15mg at screening
- Change in oral GC dose  $\leq$  2 weeks prior to screening
- Prior IVIG treatment for anti-HMGCR IMNM
- $\geq$ 1 oral conventional synthetic DMARD (e.g. methotrexate, mycophenolate mofetil, azathioprine) use at screening
- Change in concomitant DMARD dose  $\leq$  4 weeks prior to screening

... and 15 more (see full listing online)

## Locations (5 total)

---

University of Alabama at Birmingham, Birmingham, Alabama, United States

Johns Hopkins University, Baltimore, Maryland, United States

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

... and 2 more locations